logo
Chatbot Helps Users Adopt a Low FODMAP Diet

Chatbot Helps Users Adopt a Low FODMAP Diet

Medscape22-05-2025
SAN DIEGO — Low fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs) dietary advice has been shown to be effective in easing bloating and abdominal pain, especially in patients with irritable bowel syndrome (IBS), but limited availability of dietitians makes delivering this advice challenging. Researchers from Thailand have successfully enlisted a chatbot to help.
In a randomized controlled trial, they found that chatbot-assisted dietary advice with brief guidance effectively reduced high FODMAP intake, bloating severity, and improved dietary knowledge, particularly in patients with bothersome bloating.
'Chatbot-assisted dietary advice for FODMAPs restriction was feasible and applicable in patients with bloating symptoms that had baseline symptoms of moderate severity,' study chief Pochara Somvanapanich, with the Division of Gastroenterology, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand, told Medscape Medical News.
Somvanapanich, who developed the chatbot algorithm, presented the study results at Digestive Disease Week (DDW) 2025.
More Knowledge, Less Bloating
The trial enrolled 86 adults with disorders of gut-brain interaction experiencing bloating symptoms for more than 6 months and consuming more than seven high-FODMAPs items per week. Half of them had IBS.
At baseline, gastrointestinal (GI) symptoms and the ability to identify FODMAPs were assessed. All participants received a 5-minute consultation on FODMAPs avoidance from a GI fellow and were randomly allocated (stratified by IBS diagnosis and education) into two groups.
The chatbot-assisted group received real-time dietary advice via a chatbot which helped them identify high, low, and non-FODMAP foods from a list of more than 300 ingredients/dishes of Thai and western cuisines.
The control group received only brief advice on high FODMAPs restriction. Both groups used a diary app to log food intake and postprandial symptoms. Baseline bloating, abdominal pain and global symptoms severity were similar between the two groups. Data on 64 participants (32 in each group) were analyzed.
After 4 weeks, significantly more people in the chatbot group than the control group responded — achieving a 30% or greater reduction in daily worst bloating, abdominal pain or global symptoms (19 [59%] vs 10 [31%], P < .05). Responder rates were similar in the IBS and non-IBS subgroups.
Subgroup analysis revealed significant differences between groups only for participants with bothersome bloating, not those with mild bloating severity.
In those with bothersome bloating severity, the chatbot group had a higher response rate (69.5% vs 36.3%) and fewer bloating symptoms ( P < .05). They also had a greater reduction in high FODMAPs intake (10 vs 23 items/week) and demonstrated improved knowledge in identifying FODMAPs ( P < .05).
'Responders in a chatbot group consistently engaged more with the app, performing significantly more weekly item searches than nonresponders ( P < .05),' the authors noted in their conference abstract.
'Our next step is to develop the chatbot-assisted approach for the reintroduction and personalization phase based on messenger applications (including Facebook Messenger and other messaging platforms),' Somvanapanich told Medscape Medical News .
'Once we've gathered enough data to confirm these are working effectively, we definitely plan to create a one-stop service application for FODMAPs dietary advice,' Somvanapanich added.
Lack of Robust Data on Digital GI Health Apps
Commenting on this research for Medscape Medical News , Sidhartha R. Sinha, MD, Director of Digital Health and Innovation, Division of Gastroenterology and Hepatology, Stanford University in Stanford, California, noted that there is a 'notable lack of robust data supporting digital health tools in gastroenterology. Despite hundreds of apps available, very few are supported by well-designed trials.'
'The study demonstrated that chatbot-assisted dietary advice significantly improved bloating symptoms, reduced intake of high-FODMAP foods, and enhanced patients' dietary knowledge compared to brief dietary counseling alone, especially in those with bothersome symptoms,' said Sinha, who wasn't involved in the study.
'Patients actively used the chatbot to manage their symptoms, achieving a higher response rate than those in the control arm who received brief counseling on avoiding high-FODMAP food,' he noted.
Sinha said in his practice at Stanford, 'in the heart of Silicon Valley,' patients do use digital resources to manage their GI symptoms, including diseases like IBS and inflammatory bowel disease (IBD) — and he believes this is 'increasingly common nationally.'
'However, the need for evidence-based tools is critical and the lack here often prevents many practitioners from regularly recommending them to patients. This study aligns well with clinical practice, and supports the use of this particular app to improve IBS symptoms, particularly when access to dietitians is limited. These results support chatbot-assisted dietary management as a feasible, effective, and scalable approach to patient care,' Sinha told Medscape Medical News .
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Associated Press

time6 hours ago

  • Associated Press

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

SHANGHAI, July 2, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved ZEGFROVY® (sunvozertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ZEGFROVY, which has received Priority Review and Breakthrough Therapy Designation from the FDA, is the only approved targeted oral treatment for NSCLC with EGFR exon20ins. This indication is approved under Accelerated Approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 'We are proud to have developed ZEGFROVY, a first-in-class oral therapy that offers a more effective treatment option with enhanced safety and ease of administration for NSCLC patients with EGFR exon20ins,' said Dr. Xiaolin Zhang, CEO of Dizal. 'The accelerated approval of ZEGFROVY marks a significant milestone that underscores our commitment to developing groundbreaking new medicines for patients with high unmet medical needs around the world.' ZEGFROVY is an oral, irreversible EGFR inhibitor with uniquely designed molecular structure targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. In August 2023, ZEGFROVY received accelerated approval in China. Today's FDA approval follows Breakthrough Therapy Designation and Priority Review granted by both the U.S. FDA and the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The FDA approval is supported by data from the multinational pivotal study WU-KONG1 Part B (WU-KONG1B), aiming to investigate the efficacy and safety of ZEGFROVY in relapsed or refractory NSCLC with EGFR exon20ins. The study results were featured as an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and were recently published in the Journal of Clinical Oncology. 'As the world's only approved targeted oral therapy for EGFR exon20ins NSCLC, ZEGFROVY has expanded the treatment paradigm in this therapeutic area that has long lacked convenient and effective treatment options,' said Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute of Harvard Medical School and lead principal investigator of WU-KONG1B. 'Research findings from WU-KONG1B have demonstrated ZEGFROVY's significant therapeutic effects with consistent efficacy across both Asian and non-Asian patient populations. Its convenient once-daily oral dosing substantially improves administration convenience and patient adherence, which is an increasingly critical factor as lung cancer care shifts toward chronic disease management. The U.S. approval of ZEGFROVY® marks a landmark in scientific advancement and represents a meaningful milestone in addressing the long-standing unmet medical needs of this underserved patient population.' 'ZEGFROVY has demonstrated breakthrough therapeutic value in the treatment of EGFR exon20ins NSCLC, as shown in a rigorous multinational clinical trial. Its potent antitumor activity, manageable safety profile, and convenient oral administration position it as an optimal treatment option in clinical practice,' said Prof. James Chih-Hsin Yang, MD, PhD, National Taiwan University Cancer Center Hospital and the Co-lead principal investigator of WU-KONG1B. 'The approval of ZEGFROVY in major global markets not only offers new hope for patients, but also reinforces our commitment to patient-centered research and the continued advancement of precision medicine in lung cancer.' 'In NSCLC, EGFR exon20ins represent the third most common type of EGFR mutation. EGFR exon20ins are particularly challenging to treat due to their unique spatial conformation, diverse mutation subtypes, and high heterogeneity. As a result, patients face a poor prognosis and limited treatment options,' said Prof. Mengzhao Wang, MD, PhD, lead principal investigator of the China-based pivotal study WU-KONG6 of ZEGFROVY and principal investigator of WU-KONG1B at Peking Union Medical College Hospital, 'The results of the WU-KONG6 study demonstrated ZEGFROVY's clinical benefit superior to current options and lead to the drug's approval in China. The U.S. approval of ZEGFROVY will enable more patients around the world to benefit from this drug.' The FDA simultaneously approved Thermo Fisher Scientific's Oncomine™ Dx Express Test as a next-generation sequencing (NGS) companion diagnostic (CDx) for ZEGFROVY to identify NSCLC patients with EGFR Exon20 insertions. NGS testing is recognized as a critical technology in cancer genomic profiling, facilitating the rapid and precise detection of DNA mutations in tumor cells. Combined with the Ion Torrent™ Genexus™ Dx System, the test delivers NGS results in as little as 24 hours to help inform more timely treatment decisions in patients with EGFR exon20ins NSCLC. Additionally, Dizal has completed enrollment for its multinational phase III pivotal WU-KONG28 study, evaluating ZEGFROVY versus platinum-based doublet chemotherapies in treatment naïve NSCLC patients with EGFR exon20ins across 16 countries and regions. At the 2023 European Society for Medical Oncology (ESMO) Annual Meeting, Dizal reported that ZEGFROVY, as a single oral agent, achieved a confirmed objective response rate (ORR) of 78.6% and a median progression-free survival (mPFS) of 12.4 months in the first-line setting. With its potent antitumor activity and favorable safety profile, ZEGFROVY demonstrated strong potential as an optimal first-line treatment for patients with EGFR exon20ins NSCLC. About ZEGFROVY® (sunvozertinib) ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. ZEGFROVY is approved in the U.S. and China for the treatment the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy. The China approval is based on the results of the pivotal WU-KONG6 study in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The U.S. approval is supported by WU-KONG1 Part B, a multinational pivotal study investigating the efficacy and safety of ZEGFROVY in the same indication. In addition, ZEGFROVY also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations (such as G719X, L861Q, etc.), as well as HER2 exon20ins. ZEGFROVY showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse event) were Grade 1/2 in nature and clinically manageable. WU-KONG28, a phase III, multinational, randomized study assessing ZEGFROVY as a first-line treatment for patients with EGFR exon20ins NSCLC, has completed enrollment across 16 countries and regions. Pre-clinical and clinical results of ZEGFROVY were published in peer-reviewed journals Cancer Discovery, The Lancet Respiratory Medicine and Journal of Clinical Oncology. About Dizal Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies and two leading assets: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit or follow us on Linkedin or Twitter. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', and 'intend' and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal's competitive environment, and political, economic, legal, and social conditions. Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect. Contacts Investor Relations: [email protected] Business Development: [email protected] Media Contact: [email protected] View original content to download multimedia: SOURCE Dizal Pharmaceutical

Asian Market Insights: 3 Stocks That Investors Might Be Undervaluing
Asian Market Insights: 3 Stocks That Investors Might Be Undervaluing

Yahoo

time9 hours ago

  • Yahoo

Asian Market Insights: 3 Stocks That Investors Might Be Undervaluing

As global markets respond to easing trade tensions and positive economic signals, Asian indices have shown resilience, with notable gains in China and Japan. In this environment, identifying undervalued stocks becomes crucial for investors seeking opportunities amidst the broader market optimism. Name Current Price Fair Value (Est) Discount (Est) T'Way Air (KOSE:A091810) ₩2025.00 ₩4024.62 49.7% Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) CN¥111.64 CN¥222.46 49.8% SIGMAXYZ Holdings (TSE:6088) ¥1221.00 ¥2440.83 50% Shanghai OPM Biosciences (SHSE:688293) CN¥43.21 CN¥85.97 49.7% Prospect Logistics and Industrial Freehold and Leasehold Real Estate Investment Trust (SET:PROSPECT) THB7.20 THB14.35 49.8% Maxscend Microelectronics (SZSE:300782) CN¥69.87 CN¥139.59 49.9% KeePer Technical Laboratory (TSE:6036) ¥3375.00 ¥6748.76 50% Good Will Instrument (TWSE:2423) NT$43.40 NT$86.69 49.9% Forum Engineering (TSE:7088) ¥1195.00 ¥2373.59 49.7% Duk San NeoluxLtd (KOSDAQ:A213420) ₩33600.00 ₩66906.69 49.8% Click here to see the full list of 268 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's review some notable picks from our screened stocks. Overview: Genscript Biotech Corporation is an investment holding company involved in the manufacture and sale of life science research products and services across the United States, Europe, Mainland China, Asia Pacific, and internationally, with a market cap of HK$33.16 billion. Operations: The company's revenue is primarily derived from Life Science Services and Products ($454.95 million), Biologics Development Services ($95.02 million), and Industrial Synthetic Biology Products ($53.69 million). Estimated Discount To Fair Value: 31.1% Genscript Biotech is trading at HK$15.22, significantly below its estimated fair value of HK$22.09, suggesting it may be undervalued based on cash flows. Recent payments totaling US$213.8 million from ProBio bolster its cash reserves, enhancing financial stability and core competencies. While earnings are forecast to grow substantially at 65.8% per year and revenue growth outpaces the Hong Kong market, a low return on equity of 7.1% in three years presents a potential concern for investors seeking high returns. Our expertly prepared growth report on Genscript Biotech implies its future financial outlook may be stronger than recent results. Dive into the specifics of Genscript Biotech here with our thorough financial health report. Overview: Suzhou Nanomicro Technology Co., Ltd. manufactures and supplies spherical, mono-disperse particles for various industries worldwide, with a market cap of CN¥9.13 billion. Operations: The company's revenue segments include the production and distribution of spherical, mono-disperse particles for diverse industrial applications globally. Estimated Discount To Fair Value: 15.5% Suzhou Nanomicro Technology is trading at CN¥22.77, below its estimated fair value of CN¥26.96, indicating potential undervaluation based on cash flows. Earnings are expected to grow significantly at 37.9% per year, outpacing the broader Chinese market's growth rate. Recent financial results show revenue increased to CN¥188.59 million from CN¥154.1 million a year ago, with net income rising to CN¥29.22 million from CN¥16.89 million, supporting its growth trajectory despite a forecasted low return on equity of 11%. The analysis detailed in our Suzhou Nanomicro Technology growth report hints at robust future financial performance. Click here and access our complete balance sheet health report to understand the dynamics of Suzhou Nanomicro Technology. Overview: SBS Holdings, Inc. offers logistics services both in Japan and internationally, with a market cap of ¥126.90 billion. Operations: The company generates revenue from its Logistics Business, which accounts for ¥429.82 billion, and its Real Estate Business, contributing ¥10.09 billion. Estimated Discount To Fair Value: 35.5% SBS Holdings, trading at ¥3195, is significantly undervalued with a fair value estimate of ¥4956.46 according to discounted cash flow analysis. Despite profit margins declining from 1.9% to 1.3%, earnings are projected to grow at 22.44% annually, surpassing the Japanese market growth rate of 7.5%. However, the dividend yield of 2.66% isn't well covered by free cash flows and debt coverage by operating cash flow remains weak amidst planned strategic acquisitions like Bridgestone Logistics Co., Ltd.'s stock. In light of our recent growth report, it seems possible that SBS Holdings' financial performance will exceed current levels. Click here to discover the nuances of SBS Holdings with our detailed financial health report. Unlock our comprehensive list of 268 Undervalued Asian Stocks Based On Cash Flows by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1548 SHSE:688690 and TSE:2384. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store